dapivirine ring

  • HOPE and Beyond: Next Steps and Planned Studies of the Dapivirine Vaginal Ring

    The HIV Open-Label Extension (HOPE) study offers former participants in the ASPIRE study of the dapivirine vaginal ring the opportunity to use the ring in the context of a study while researchers collect additional data on safety and adherence. This Q&A document provides information about HOPE and other studies of the dapivirine ring, including REACH, which will evaluate how adolescent girls and young women use the monthly ring and daily oral pre-exposure prophylaxis.

  • After The Ring Study: DREAM

    A follow-on to The Ring Study of a dapivirine ring, the Dapivirine Ring Extended Access and Monitoring (DREAM) open-label extension study is providing the active ring to former Ring Study participants — and young women using the ring for the first time — while the product is under regulatory review for licensure.

  • The Promise of the Ring for Women’s HIV Prevention

    Watch this video to learn about the dapivirine vaginal ring and the International Partnership for Microbicide’s next steps to potentially put the product into the hands of women at high risk of HIV.

  • Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women

    The results of The Ring Study, a randomized controlled trial that evaluated the safety and efficacy of extended use of a vaginal ring containing dapivirine for the prevention of HIV infection among women in South Africa and Uganda,were published December 1, 2016, in The New England Journal of Medicine. The authors concluded that the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.

  • The Dapivirine Ring Design Guide: Human-Centered Design Research to Increase Uptake and Use

    This guide provides an overview of design concepts to promote sustained use of the dapivirine ring and describes how the concepts were developed through a human-centered design approach. The guide also provides a link to a supplementary library of online resources, such as editable templates and supporting visuals, that can be used to adapt selected concepts.

  • Microbicides: Women-Centered HIV Prevention Products to Help End AIDS by 2030

    The International Partnership for Microbicides explains why microbicide research and development is a smart investment for women’s health, economic growth, and gender equality.

  • FACTS 001 Trial: Questions and Answers

    Questions and answers about the FACTS 001 efficacy trial of the use of tenofovir vaginal gel among women in South Africa provide background on the study and information about its results and their implications.

Pages